Clinical Utility Pilot Of Thyroid GuidePx
The purpose of this research study is learn about the effects of Thyroid GuidePx® on papillary thyroid cancer treatment recommendations when the test result is disclosed after surgery.
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Descrizione dettagliata
Primary Objectives:
To determine the decision impact of Thyroid GuidePx® when results are disclosed postoperatively, defined across three prespecified decision domains:
- Extent of initial surgery (counterfactual): (i) among patients who actually had a total thyroidectomy, through the post-test clinician survey, whether Thyroid GuidePx® results would have changed surgical extent and lobectomy would have been appropriate. This includes patients who underwent intraoperative conversion from lobectomy to total thyroidectomy due to gross extrathyroidal extension or unexpected central nodal metastases. (ii) Among patients who actually had a lobectomy, the post-test clinician survey will record whether, knowing the Thyroid GuidePx® result, total thyroidectomy would have been appropriate (Yes/No), providing a counterfactual measure of potential treatment escalation.
- Completion thyroidectomy: whether Thyroid GuidePx® results change the recommendation to perform completion thyroidectomy or not to perform completion thyroidectomy.
- Adjuvant RAI: Whether Thyroid GuidePx® results change the recommendation to administer postoperative RAI or not to administer postoperative RAI.
Secondary Objectives:
- To estimate the proportion of decision changes within each prespecified domain and the net direction (escalation vs de-escalation).
- To explore clinician- and patient-reported drivers of decision change.
- To assess postoperative decisional regret following disclosure of Thyroid GuidePx® results using the Decisional Regret Scale (DRS), and to explore associations with surgical extent and molecular risk category.
- To compare the proportion of patients who had a completion thyroidectomy in patients who underwent Thyroid GuidePx® testing to historical controls.
- To compare recurrence outcomes in patients whose treatment was de-escalated based on Thyroid GuidePx® result to matched historical controls at the same institution.
Tipo di studio
Tipo di studio
Iscrizione (Stimato)
Iscrizione
Contatti e Sedi
Contatto studio
Contatto studio
- Nome: Anastasios Maniakas, MD
- Numero di telefono: 713-792-4351
- Email: amaniakas@mdanderson.org
Luoghi di studio
-
-
Texas
-
Houston, Texas, Stati Uniti, 77030
- UT MD Anderson
-
Contatto:
- Anastasios Maniakas, MD
- Numero di telefono: 713-792-4351
- Email: amaniakas@mdanderson.org
-
Investigatore principale:
- Anastasios Maniakas, MD
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Metodo di campionamento
Popolazione di studio
UT MD Anderson
Descrizione
Inclusion Criteria:
disease who can potentially be treated with lobectomy will be recruited to the study. Lobectomy-candidate status is determined by the treating physician using standard institutional criteria (e.g., tumor 1-4 cm, cN0/Nx, no gross ETE). Patients may still undergo total thyroidectomy as part of shared decision-making.
Inclusion criteria:
-
Patients aged 18 years or older at the time of enrollment
-
English-speaking
-
Bethesda V or VI cytology following FNA of a thyroid nodule (papillary thyroid cancer)
-
Preoperative candidacy for lobectomy
- Tumor 1 - 4 cm in size
- No known nodal metastasis
- No gross extrathyroidal extension (ETE) on ultrasound
-
Any of the following intraoperative or surgeon-dependent variations are permitted:
- Prophylactic ipsilateral central neck dissection performed at the surgeon's discretion
- Therapeutic central neck dissection for unexpected central node metastases
- Intraoperative conversion to total thyroidectomy (e.g., gross ETE, multiple large central nodes)
-
Able to undergo intraoperative FNA collection for research testing
Exclusion Criteria:
- Prior thyroid operation
- Distant metastatic disease
- Personal history of thyroid cancer
- History of whole-body radiation exposure or radiation to the head and neck region
- Preoperatively known central or lateral lymph node metastasis
- Receipt of total thyroidectomy is not an exclusion if preoperative features otherwise meet lobectomy-candidate criteria
Patients remain eligible if unexpected central nodal disease is identified intraoperatively or if the surgeon elects to perform a prophylactic ipsilateral central neck dissection, as these scenarios are compatible with initial lobectomy candidacy at MD Anderson.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Modelli osservazionali: CASE_ONLY
- Prospettive temporali: PROSPECTIVE
Numero di gruppi/coorti
Coorti e interventi
Gruppo / CoorteGruppo / Coorte |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
All Patients
Eligible participants will be identified during standard preoperative evaluation for thyroid nodules or confirmed PTC, following cytological diagnosis (Bethesda V or VI). |
Participants will be offered enrollment in this study, in which Thyroid GuidePx® will be performed on an intraoperative FNA (ioFNA) collected during surgery, with results disclosed postoperatively. |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Decision Impact. There are three domain-specific endpoints
Lasso di tempo: Through study completion; an average of 1 year
|
Extent of initial surgery (counterfactual). (i) Among patients who actually had total thyroidectomy, the post-test clinician survey will record whether, knowing the Thyroid GuidePx® result, would have changed surgical extent. Specifically, if lobectomy would have been appropriate (Yes/No), providing a counterfactual measure of potential de-escalation. (ii) Among patients who actually had a lobectomy, the post-test clinician survey will record whether, knowing the Thyroid GuidePx® result, total thyroidectomy would have been appropriate (Yes/No), providing a counterfactual measure of potential treatment escalation. b) Completion thyroidectomy. Proportion with a change in recommendation (Yes→No or No→Yes). c) Adjuvant RAI. Proportion with a change in recommendation (Yes→No or No→Yes) and intended dose if Yes. |
Through study completion; an average of 1 year
|
Collaboratori e investigatori
Sponsor
Sponsor
Investigatori
Investigatori
- Investigatore principale: Anastasios Maniakas, MD, UT MD Anderson
Pubblicazioni e link utili
Collegamenti utili
Studiare le date dei record
Studia le date principali
Inizio studio (Stimato)
Inizio studio
Completamento primario (Stimato)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
- Malattie del sistema endocrino
- Neoplasie per sede
- Neoplasie
- Neoplasie per tipo istologico
- Neoplasie tiroidee
- Neoplasie delle ghiandole endocrine
- Neoplasie della testa e del collo
- Neoplasie, ghiandolari ed epiteliali
- Adenocarcinoma
- Carcinoma
- Malattie della tiroide
- Adenocarcinoma, papillare
- Cancro alla tiroide, papillare
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- 2026-0272
- NCI-2026-08256 (Altro identificatore: NCI-CTRP Clinical Trials Registry)
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .